Adipocyte FABP (AFABP, FABP4) Human ELISA

Research topic

Energy metabolism and body weight regulation

Features

• The total assay time is less than four hours.
• The kit measures total serum or plasma AFABP.
• Quality Controls are human serum based. No animal sera are used.

Patent Application Number: DE 10 2005 034 788.6

Storage/Shipping

Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Summary

Adipocyte fatty acid binding protein AFABP is a 15 kDa member of the intracellular fatty acid binding protein (FABP) family, which is known for the ability to bind fatty acids and related compounds (bile acids or retinoids) in an internal cavity. AFABP is expressed in a differentiation-dependent fashion in adipocytes and is a critical gene in the regulation of the biological function of these cells . In mice, targeted mutations in AFABP provide significant protection from hyperinsulinemia and insulin resistance in the context of both dietary and genetic obesity. Adipocytes obtained from AFABP-deficient mice also have reduced efficiency of lipolysis in vitro and in vivo, and these mice exhibited moderately improved systemic dyslipidemia. Recent studies also demonstrated AFABP expression in macrophages upon differentiation and activation. In these cells, AFABP modulates inflammatory responses and cholesterol ester accumulation, and total or macrophage-specific AFABP deficiency confers dramatic protection against atherosclerosis in the apoE^-/- mice. These results indicate a central role for AFABP in the development of major components of the metabolic syndrome through its distinct actions in adipocytes and macrophages.

Assay format

Sandwich ELISA, Biotin-labelled antibody

Sample requirements

10 µl/well

Applications

Cell culture medium, Plasma-Citrate, Plasma-EDTA, Plasma-Heparin, Serum, Tissue extract

Calibration Curve

Calibration range

0.5 to 25 ng/ml

Limit of detection

Analytical Limit of Detection is calculated from the real human AFABP values in wells and is 0.1 ng/ml.

Limit of quantification

Assay Sensitivity takes the dilution of samples into consideration and is calculated according to the formula: Assay Sensitivity = Analytical Limit of Detection x sample dilution = 0.1ng/ml x 10 = 1ng/ml

Intra-assay (Within-Run, n=8)

CV = 5.3 %

Inter-assay (Run-to-Run, n=3)

CV = 3.9 %

Spiking Recovery

105.6 %

Dilution Linearity

107.1 %

Cross-Reactivity

Human, Cat, Dog, Monkey

Find out more on biovendor.com

• Adipocyte fatty-acid-binding protein in BioVendor News

References to this product

• von Eynatten M, Schneider JG, Allolio B . Adipocyte fatty acid binding protein (A-FABP) ist ein neuer Serum-Marker für Adipositas, Insulinresistenz und Metabolisches Syndrom. Diabetologie . 1:S23-S172 (2006)
• Stejskal D, Karpisek M . Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?. Eur J Clin Invest . Sep;36(9):621-5 (2006)
• Reinehr T, Stoffel-Wagner B, Roth CL. Adipocyte fatty acid-binding protein in obese children before and after weight loss. Metabolism. 2007 Dec;56 (12):1735-41
• Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS . Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem . Mar;52(3):405-13 (2006)
• Bronsky J, Karpisek M, Bronska E, Pechova M, Jancikova B, Kotolova H, Stejskal D, Prusa R, Nevoral J . Adiponectin, adipocyte fatty acid binding protein, and epidermal fatty acid binding protein: proteins newly identified in human breast milk. Clin Chem . Sep;52(9):1763-70 (2006)
• Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS . Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation . Mar 27;115(12):1537-43 (2007)
• von Eynatten M, Luzzi VI, Allolio B, Semenkovich CF, Schneider JG . Circulating Adipocyte-Specific Fatty Acid Binding Protein Levels Are Elevated in Type 2 Diabetes and Coronary Artery Disease.
• Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L . Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis . Nov;195(1):e150-e158 (2007)
• Ben Yahia R, Lichnovska R, Gwozdiewiczova S, Kuzmina G, Chlup R, Luza J, Karpisek M, Brychta T, Petrek J . Fatty Acid Binding Proteins (FABPS) in relation to significant metabolic syndrome markers in diabetic patients and non-diabetic persons - pilot study. Int J Obesity . 29: S1-S19
• Ben Yahia R, Lichnovska R, Janusova L, Kuzmina G, Karpisek M, Kollar P, Petrek J . Healthy persons versus patients with diabetes mellitus type 2--choosen parameters in serum and subcutaneous abdominal adipose tissue. Vnitr Lek. Jan;53(1):9, 11-7 (2007)
• Haider DG, Schindler K, Bohdjalian A, Prager G, Luger A, Wolzt M, Ludvik B . Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. Diabetes Obes Metab . Mar 13 (2007)
• Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L . Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem . Jan;54(1):181-7 (2008)
• Gul O, Calay E, Sezerman U, Basaga H, Gurbuz Y . Sandwich-type, antibody microarrays for the detection and quantification of cardiovascular risk markers. Chemical . Aug 125(2):581-588 (2007)
• Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, Cheung BM, Janus ED, Lam KS . Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes - a 10-year prospective study in Chinese. Diabetes Care . Jul 9 (2007)
• Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS . Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol . Aug;27(8):1796-802 (2007)
• Coll B, Cabre A, Alonso-Villaverde C, Lazaro I, Aragones G, Parra S, Girona J, Masana L . The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis . Nov 3 (2007)
• Karpisek M, Stejskal D, Kotolova H, Kollar P, Janoutova G, Ochmanova R, Cizek L, Horakova D, Yahia RB, Lichnovska R, Janout V . Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest . Aug;37(8):637-42 (2007)

References to summary

• Makowski L, Brittingham KC, Reynolds JM, Suttles J and Hotamisligil GS: The Fatty Acid-binding Protein, aP2, Coordinates Macrophage Cholesterol Trafficking and Inflammatory Activity. J Biol Chem. 2005 Apr 1.280(13):12888–95.
• Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, AtsumiG, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA and Hotamisligil GS: Adipocyte/macrop­hage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metabolism, Volume 1, Issue 2, February 2005, Pages 107–119.
• Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS: Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004 Sep 14;110(11):1492–8.
• Lehmann F, Haile S, Axen E, Medina C, Uppenberg J, Svensson S, Lundback T, Rondahl L, Barf T: Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445–8.
• Damcott CM, Moffett SP, Feingold E, Barmada MM, Marshall JA, Hamman RF, Ferrell RE: Genetic variation in fatty acid-binding protein-4 and peroxisome proliferatorac­tivated receptor gamma interactively influence insulin sensitivity and body composition in males. Metabolism. 2004 Mar;53(3):303–9.
• Jenkins-Kruchten AE, Bennaars-Eiden A, Ross JR, Shen WJ, Kraemer FB, Bernlohr DA: Fatty acid-binding protein-hormone-sensitive lipase interaction. Fatty acid dependence on binding. J Biol Chem. 2003 Nov 28;278(48):47636–43.
• Hertzel AV, Bennaars-Eiden A, Bernlohr DA: Increased lipolysis in transgenic animals overexpressing the epithelial fatty acid binding protein in adipose cells. J Lipid Res. 2002 Dec;43(1­2):2105–11.
• Fu Y, Luo N, Lopes-Virella MF, Garvey WT: The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis. 2002 Dec;165(2):259–69.
• Storch J, Veerkamp JH, Hsu KT: Similar mechanisms of fatty acid transfer from human anal rodent fatty acid-binding proteins to membranes: liver, intestine, heart muscle, and adipose tissue FABPs. Mol Cell Biochem. 2002 Oct;239(1–2):25–33.
• Fisher RM, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M: Effects of obesity and weight loss on the expression of proteins involved in fatty acid metabolism in human adipose tissue. Int J Obes Relat Metab Disord. 2002 Oct;26(10):1379–85.
• Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS: Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholeste­rolemia. Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1686–91.
• Fisher RM, Eriksson P, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M, Hamsten A, Arner P: Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia. 2001 Oct;44(10):1268–73.
• Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, Morgan M, Parker RA, Hotamisligil GS: Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes. 1999 Oct;48(10):1987–94.
• Coe NR, Simpson MA, Bernlohr DA: Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res. 1999 May;40(5):967–72.
• Baxa CA, Sha RS, Buelt MK, Smith AJ, MatareseV, Chinander LL, Boundy KL and Bernlohr DA: Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. Biochemistry. 1989; 28 (22), 8683–8690.